全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2016 

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

DOI: 10.21037/atm.2016.05.48

Full-Text   Cite this paper   Add to My Lib

Abstract:

Treatment for advanced non-small cell lung cancer (NSCLC) depends on the molecular characteristics of the tumor. Mutations of the gene for the epidermal growth factor receptor (EGFR) are present in ~32% of Asians and ~7% of individuals of other ethnic groups with NSCLC, with deletions in exon 19 and an L858R point mutation in exon 21 accounting for ~90% of such genetic alterations detected at diagnosis (1). NSCLC tumors that harbor EGFR mutations are oncogene addicted and therefore usually sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs)

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133